The global sales of temporary pacing leads are estimated to be worth USD 369.79 million in 2024 and are anticipated to reach a value of USD 519.56 million by 2034. Sales are projected to rise at a CAGR of 3.5% over the forecast period between 2024 and 2034. The revenue generated by temporary pacing leads in 2023 was USD 357.88 million.
The temporary pacing leads are thin, flexible wires used to carry electrical impulses to the heart, which regulates its rhythm temporarily. These can be used in instances where the heart rate of a patient is too slow-bradycardia-or irregular, where immediate intervention is required to maintain a stable heart rhythm.
They are normally inserted through a vein and then connected to an external pacemaker, which sends the electrical impulses. The market of temporary pacing lead is growing with the aging of the population and increasing incidence of cardiovascular diseases.
Apart from it some other contributing factors to such growth include technological advancement within the field of medical devices and the rising demand for minimally invasive procedures. The healthcare industry is shifting toward patient-centric care and hence demanding effective and versatile cardiac solutions like temporary pacing leads, since they are in high demand in emergency and perioperative cardiac care.
Global Temporary Pacing Leads Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 357.88 million |
| Estimated Size, 2024 | USD 369.79 million |
| Projected Size, 2034 | USD 519.56 million |
| Value-based CAGR (2024 to 2034) | 3.5% |
There is a significant rise in open-heart surgeries and as well as aortic valve regurgitation cases which has led to rise of transcatheter aortic valve replacement (TAVR) procedures and thus increased demand for temporary pacing leads.
These procedures often involve intricate manipulations of the heart or placement of devices near critical cardiac structures, which can disrupt the heart's natural electrical pathways. As a result, patients undergoing these interventions are at heightened risk of developing temporary or permanent conduction abnormalities.
The increasing prevalence of cardiovascular diseases and the aging population contribute to a rising volume of these procedures globally. For instance, according to an article published by the Detroit Medical Center in August 2020, approximately 500,000 people in the USA undergo open-heart surgery each year for the correction of various cardiovascular diseases.
According to an article published by the National Library of Medicine in August 2023, around 27,223 TAVI procedures were conducted in 147 TAVI centers across 26 European countries in 2021.
This increase in procedure numbers significantly contributes to the demand for temporary pacing leads, as they aid in the management of cardiovascular diseases and play a crucial role in stabilizing and regulating the heart's rhythm during the immediate post-procedural period.
Moreover, these devices have the ability to deliver electrical impulses directly to the heart, ensuring adequate cardiac output and preventing hemodynamic instability, which contributes to their increased adoption rate.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The above table presents the expected CAGR for the global temporary pacing leads market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 4.5%, followed by a slightly decline in growth rate of 4.1% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 4.5% (2023 to 2033) |
| H2 | 4.1% (2023 to 2033) |
| H1 | 3.5% (2024 to 2034) |
| H2 | 3.0% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 3.5% in the first half and decrease moderately at 3.0% in the second half. In the first half (H1) the market witnessed a decrease of -100.00 BPS while in the second half (H2), the market witnessed a decrease of -110.00 BPS.
Growing Number of New Product Launches as well as Improved Reimbursement Policies the Market for Temporary Pacing Leads is Continue to Grow in Upcoming Years
The reimbursement policies properly address the TPL-related costs and the procedure costs, they are more willing to carry out the implementation without financial worries. This increases application in many clinical environments such as ICUs, cardiac catheterization laboratories, and operating theaters where there is a great role of TPLs in the management of acute cardiac rhythm disturbances after surgery or during critical care.
Apart from it favorable reimbursement policies make it encouraging for the healthcare professional to consider TPLs as a standard of care in those who are going to need temporary cardiac pacing. This acceptance of TPLs is important, especially in emergent situations like post-heart surgeries or those with serious arrhythmias, where timely interventions with TPLs will save lives.
The continuous innovation and competitive pressures in cardiac care have raised the competition graph to introduce competitively priced products into the market. The competitive climate, in turn, will motivate manufacturers to invest in research and development, further driving technological advancement and improving overall quality.
Also most of the manufacturers, in a bid to meet the changing clinical needs and preferences of healthcare, have their focus on launching new products in the market, offering health providers an array of options that best suit the varied population.
For instance, in January 2020, Teleflex Incorporated, a global provider of medical technologies, received USA FDA clearance for its WattsonTM temporary pacing guidewire. This bipolar temporary pacing guidewire is specifically designed for use during transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV).
Hence the market for owing to the favorable reimbursement policies as well as new product launches the temporary pacing leads sales is anticipated.
Expanding Use in Complex Cardiac Procedures is Among the Key Trend in Temporary Pacing Leads Market
In recent year the temporary pacing leads being increasingly used in these complex and specialized cardiac procedures, such as structural heart interventions and electrophysiology studies.
In structural heart interventions, the procedures include, transcatheter aortic valve replacements and mitral valve repairs, temporary pacing leads are playing important role during and immediately following the procedure in order to manage the rhythms of the heart.
These leads are responsible for maintaining the heart rate and rhythm steady, offsetting the disturbing effect brought about by the intervention.
Similarly, in electrophysiology studies that diagnose and treat arrhythmias, temporary pacing leads allow for precise mapping and manipulative maneuvers of electrical pathways of the heart. They provide necessary control over heart rate and rhythm, enabling cardiologists to perform intricate diagnostic and therapeutic maneuvers safely.
This can be attributed to the ever-expanding use of temporary pacing leads, primarily based on key trends in market growth. With the continuously rising prevalence of complex cardiac conditions and greater adoption of advanced minimally invasive procedures, demands for continuous and reliable pacing solutions continue to rise.
Finally, technological advances have enhanced functionality and usability in temporary pacing leads, making them even more appealing for healthcare professionals. The trend broadens the market scope, underlining the role of temporary pacing leads as indispensable to contemporary cardiac care, consequently fostering deeper market penetration and continued growth.
The Complexities Associated with Insertion of Temporary Pacing Leads Could Lower its Adoption Rate
Temporary pacing leads (TPLs) are important tool for managing acute cardiac rhythm disturbances but pose procedural complexities. Inserting the leads requires precise placement within or near the heart, demanding skilled practitioners to navigate anatomical variations and ensure effective pacing.
Risks associated with TPLs include vascular injury, cardiac perforation, and pneumothorax, particularly with subclavian vein access. These risks necessitate meticulous technique, real-time imaging, and vigilant monitoring to mitigate complications.
Furthermore, serious complications such as cardiac perforation (up to 4%) and dislodgment (10% to 37%) with loss of pace capture can occur. These intraprocedural risks significantly impact post-procedural use, confining patients to bed rest and contributing to costly lengths of stay (LOS) in the intensive care unit.
The presence of electromagnetic interference (EMI) from nearby medical equipment can disrupt pacing signals, requiring shielding techniques and careful device management. Moreover, the placement of pacing leads carries a potential risk of infection, necessitating strict aseptic practices and post-procedure surveillance.
Therefore, while TPLs are essential for managing acute cardiac conditions, their use during procedures involves technical challenges and risks of complications. This complexity can create hesitation among healthcare providers regarding adoption and may limit their market growth.
Emphasis on Strategic Acquisitions for Expanding Geographical Presence is Creating Opportunities in the Temporary Pacing Leads Market
This expansion in new emerging markets opens up growth within healthcare infrastructures and thereby boosts the demand for advanced medical technologies. Such a strategic expansion opens one's services to an expanded end user base, including health facilities and providers that require temporary pacing solutions to assist with the management of cardiac conditions.
Geographical expansion reduces dependence on particular markets, disperses sources of revenue, and reduce risk because of economic fluctuation or changes in regulatory policies in established regions.
Besides, geographic expansion by a manufacturer allows the company to use regional differences in health needs, preferences, and regulatory environments to the full advantage of developing and marketing product offerings that are tailored to specific needs.
With a local presence, the market is more penetrated because access is improved, customer service at the local level will more readily be available, and responsiveness to changes in the market will be accentuated.
The company has closer relationships with health professionals and with distribution partners-developing trust and loyalty. In this manner, strategic partnerships with local distributors and healthcare networks improve market access and enable more efficient distribution channels.
For instance, in February 2023 Abbott signed a definitive agreement for the acquisition of Cardiovascular Systems, Inc., a medical device company specializing in innovative atherectomy systems used in the treatment of peripheral and coronary artery disease.
Hence such expansion of key players in untapped market is creating opportunities of temporary pacing leads market growth.
Principal Consultant
The global temporary pacing leads industry recorded a CAGR of 2.7% during the historical period between 2019 and 2023. The growth of temporary pacing leads industry was positive as it reached a value of USD 357.88 million in 2023 from USD 321.46 million in 2019.
Historically, temporary pacing leads were first utilized in the management of bradycardia and heart block, particularly during emergencies or in a perioperative care context. These served as important devices that helped in the stabilization of patients' heart rhythms when their natural peacemaking was compromised and acted as a bridge to more permanent measures, such as the implantation of a permanent pacemaker.
The indications of such leads were initially limited to these few emergency and perioperative scenarios. However, with the evolution of cardiac care, their indications expanded considerably. With the advancement of cardiac surgery, especially minimally invasive surgery and electrophysiology studies, the indications of temporary pacing leads went beyond conventional ones.
The future opportunity looks much promising for temporary pacing leads, owing to an uptick in cardiovascular diseases, aging of the population, and complex cardiac interventions. The growth prospects could be further helped by increased adoption for specialized procedures including structural heart interventions and electrophysiology applications.
Further, continuous development with respect to the design of leads and their integration with digital health will go further in opening new pathways for market growth; it is here that temporary pacing leads could assume a very important role as part of modern cardiac care.
Tier 1 companies comprise market leaders with a market revenue of above USD 209.98 million capturing significant market share of 58.4% in global market. These companies are targeting further market exposure through new geographical regions and diversified product offerings.
This includes targeting emerging markets within Asia-Pacific that are recording growth in disposable incomes and improving healthcare infrastructure. Prominent companies in tier 1 include Medtronic plc, Abbott and BD.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 25.0% market share. They typically pursue partnerships with academic institutions and research organizations to leverage emerging technologies and expedite product development.
These companies often emphasize agility and adaptability, allowing them to quickly bring new treatments to market, sometimes targeting specific types of cancer or rare conditions. Additionally, they focus on cost-effective production methods to offer competitive pricing. Prominent companies in tier 2 include B. Braun SE, Zimmer Biomet and Teleflex Incorporated.
Finally, Tier 3 companies, such as Oscor Inc, BioTrace Medical (Merit Medical Systems Inc.), Edwards Lifesciences Services GmbH and OSYPKA MEDICAL. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the temporary pacing leads sales remains dynamic and competitive.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the temporary pacing leads market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with higher market share through 2034. In South Asia Pacific, India is projected to witness a CAGR of 6.6% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| USA | 2.1% |
| Germany | 1.9% |
| China | 6.2% |
| France | 4.9% |
| India | 6.6% |
| Spain | 3.0% |
| Australia & New Zealand | 4.9% |
| South Korea | 5.8% |
USA temporary pacing leads market is poised to exhibit a CAGR of 2.1% between 2024 and 2034. Currently, USA holds lion’s share in the North American Temporary Pacing Leads market, and the trend is expected to continue during the forecast period.
Increasing prevalence of cardiovascular disorders, rising number of cardiac procedures and demand for temporary pacing leads in market in the USA is developing mainly owing to the increase in the prevalence of cardiovascular diseases. Heart disease continues to be the major cause of mortality in the country, which fosters the demand for advanced cardiac care solutions even more.
A large population aged above 65 years and a high incidence of various conditions like bradycardia and arrhythmias are some of the major reasons contributing to this trend. Moreover, the strong healthcare infrastructure and awareness about treatment in USA promotes the adoption of the such medical technologies, which further accelerates the growth of the market for easy availability and usage of temporary pacing leads.
China’s temporary pacing leads market is poised to exhibit a CAGR of 6.2% between 2024 and 2034. Currently, it holds the highest share in the East Asia market, and the trend is expected to continue during the forecast period.
The China’s healthcare sector is developing owing to higher investment by the government in the country's, are contributing factors to the continuous growth of China's temporary pacing lead market. The key reason is that cardiac care services have been emphasized in general healthcare reforms undertaken by the Chinese government.
The National Health Commission of China announced that the country would continue to promote access to high-value medical devices, such as temporary pacing leads, in both urban and rural areas. As such, the move is driving adoption, especially as more hospitals are acquiring the necessary technologies to conduct complex cardiac procedures.
India’s temporary pacing leads market is poised to exhibit a CAGR of 6.6% between 2024 and 2034. Currently, it holds the highest share in the South Asia & Pacific market, and the trend is expected to continue during the forecast period.
This growing awareness of cardiovascular conditions and early diagnoses is driving growth within the temporary pacing leads market in India. The public health campaigns and the efforts by organizations such as the Indian Heart Association have brought much awareness about heart diseases, thus leading to timely interventions.
For instance, in September 2022, the Hindu’s Future India Club, in association with the city’s Andhra Hospital has organized awareness programme on the occasion of World Heart Day in Vijayawada, Andhra Pradesh.
It can also be attributed to a growing middle-class population that enjoys better access to health care. Because of early diagnosis and treatment, more patients require temporary pacing lead, so the demand is getting higher, especially in towns and cities where health care facilities are getting better.
Owing to having Wide Application and Advanced Technology available in Cardiac Pacing Leads/Catheters has Higher Adoption Rate.
| By Product | Cardiac Pacing Leads/Catheter |
|---|---|
| Value Share (2024) | 95.3% |
The wide application and advanced technology available in cardiac pacing leads/catheters has hold significant market share of 95.3% in 2024. Cardiac pacing leads/catheters have a wider range of application from temporary to permanent pacing in all cardiac procedural settings.
Their unique design also allows for precise placement and reliable performance, essential in the management of arrhythmias and heart block. Cardiac pacing wires, on the other hand, are usually indicated in more specific, limited scenarios, including short-term pacing after cardiac surgery. The versatility, along with reliability and advanced features bestowed on leads/catheters, propels their dominance in the market.
| By Formulation | Transcatheter aortic valve replacement (TAVR) |
|---|---|
| Value Share (2024) | 24.6% |
The segment of TAVR holds a share of 24.6% compared with other applications, due to the increased adoption of minimally invasive procedures for the treatment of severe aortic stenosis. TAVR offers much less invasiveness than an open-heart surgical option, especially in a high-risk patient such as an elderly or any comorbid patient.
Performances from TAVR procedures are increasing with the growth in the aging population and its increasing prevalence rate of aortic stenosis. Success with TAVR and lower recovery times, along with rapid advances in transcatheter technologies, make the application preferred over cardiothoracic surgeries or treatments for acute myocardial infarction.
The market players are using strategies to stay competitive, such as product differentiation through innovative formulations, strategic partnerships with healthcare providers for distribution. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.
Recent Industry Developments in Temporary Pacing Leads Market
In terms of product, the industry is divided into-cardiac pacing leads/catheter (temporary unipolar pacing leads, temporary bipolar pacing leads [bipolar pacing leads with flexible ends] bipolar pacing leads with balloons, temporary quadripolar pacing leads) and cardiac pacing wires (uni-polar temporary pacing wires, bi-polar temporary pacing wires, quadri-polar temporary pacing wires).
In terms of application, the industry is segregated into cardiothoracic surgeries, acute myocardial infarction, bradycardia, heart blocks, sick sinus syndrome, congestive heart failure (CHF), and transcatheter aortic valve replacement (TAVR).
In terms of age group, the industry is segregated into adult and pediatric.
In terms of technique, the industry is segregated into epicardial pacing transvenous pacing and transcutaneous pacing.
In terms of end user, the industry is segregated into hospitals (less than 100 bed hospitals, 100-200 bed hospitals, more than 200 beds hospitals) and independent catheterization labs.
Key countries of North America, Latin America, Western Europe, Eastern, South Asia & Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global temporary pacing leads market is projected to witness CAGR of 3.5% between 2024 and 2034.
The global temporary pacing leads industry stood at USD 357.88 million in 2023.
The global temporary pacing leads market is anticipated to reach USD 519.56 million by 2034 end.
India is set to record the highest CAGR of 6.6% in the assessment period.
The key players operating in the global temporary pacing leads market include Medtronic plc, Abbott, BD, B. Braun SE, Zimmer Biomet, Teleflex Incorporated, Oscor Inc, BioTrace Medical (Merit Medical Systems Inc.), Edwards Lifesciences Services GmbH, OSYPKA MEDICAL, Taisho Biomed Instruments Co., Ltd., APC Cardiovascular Ltd, Lotus Surgicals Pvt Ltd, and Centenial Surgical Suture Ltd.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-Economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Product 5.2. By Application 5.3. By Age Group 5.4. By Technique 5.5. By End User 5.6. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 6.1. Cardiac Pacing Leads/Catheter 6.1.1. Temporary Unipolar Pacing Leads 6.1.2. Temporary Bipolar Pacing Leads 6.1.2.1. Bipolar Pacing Leads with Flexible Ends 6.1.2.2. Bipolar Pacing Leads with Balloons 6.1.3. Temporary Quadripolar Pacing Leads 6.2. Cardiac Pacing Wires 6.2.1. Uni-Polar Temporary Pacing Wires 6.2.2. Bi-Polar Temporary Pacing Wires 6.2.3. Quadri-Polar Temporary Pacing Wires 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 7.1. Cardiothoracic Surgeries 7.2. Acute Myocardial Infarction 7.3. Bradycardia 7.4. Heart Blocks 7.5. Sick Sinus Syndrome 7.6. Congestive heart failure (CHF) 7.7. Transcatheter aortic valve replacement (TAVR) 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Age Group 8.1. Pediatric 8.2. Adult 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technique 9.1. Epicardial Pacing 9.2. Transvenous Pacing 9.3. Transcutaneous Pacing 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 10.1. Hospitals 10.1.1. Less than 100 Bed Hospitals 10.1.2. 100-200 Bed Hospitals 10.1.3. More than 200 Beds Hospitals 10.2. Independent Catheterization Labs 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 11.1. North America 11.2. Latin America 11.3. Western Europe 11.4. Eastern Europe 11.5. South Asia & Pacific 11.6. East Asia 11.7. Middle East & Africa 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 19. Sales Forecast 2024 to 2034 By Product, By Application, By Age Group, By Technique, By End User Form for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 21. Company Profile 21.1. Medtronic plc 21.2. BioTrace Medical (Merit Medical Systems Inc.) 21.3. B. Braun SE 21.4. Oscor Inc 21.5. OSYPKA MEDICAL 21.6. BD 21.7. Abbott 21.8. APC Cardiovascular Ltd 21.9. Teleflex Incorporated 21.10. Lotus Surgicals Pvt Ltd 21.11. Centenial Surgical Suture Ltd 21.12. Taisho Biomed Instruments Co., Ltd. 21.13. Edwards Lifesciences Services GmbH 21.14. Zimmer Biomet
Healthcare
June 2023
REP-GB-12575
220 pages
Explore Healthcare Insights
View Reports
Temporary Pacing Leads Market
